Titration is the most critical phase of GLP-1 agonist therapy. The goal is not to reach the maximum dose as quickly as possible — it is to find the minimum effective dose that produces clinically meaningful weight loss and metabolic improvement while keeping side effects tolerable. Rushing titration is the most common cause of GLP-1 therapy failure, because severe nausea and GI distress cause patients to discontinue before reaching a therapeutic dose.

Principles of GLP-1 titration

Three principles govern effective titration.

Start low. The starting dose is deliberately sub-therapeutic. Its purpose is to allow the body to adapt to GLP-1 receptor activation — particularly the delayed gastric emptying and central nausea signaling that produce the most prominent early side effects.

Escalate gradually. Each dose increase reintroduces a degree of GI adjustment. Spacing escalations by at least 4 weeks (and longer if needed) gives the GI tract time to adapt before the next increase.

Hold when necessary. If a dose escalation produces intolerable side effects, the correct response is to hold at the current dose for an additional 2-4 weeks — not to push through or discontinue. Many patients stabilize at an intermediate dose and achieve excellent results without ever reaching the maximum approved dose.

Semaglutide titration protocol

FDA-approved titration schedule (Wegovy)

Week	Dose	Frequency	Purpose
1-4	0.25 mg	Once weekly	Adaptation
5-8	0.5 mg	Once weekly	Transition
9-12	1.0 mg	Once weekly	Therapeutic range entry
13-16	1.7 mg	Once weekly	Dose optimization
17+	2.4 mg	Once weekly	Full therapeutic dose

Total time to maximum dose: 16-20 weeks (4-5 months).

Practical modifications

Extended adaptation at 0.25 mg: If nausea is significant during the first 4 weeks, extend the 0.25 mg phase to 6-8 weeks. There is no penalty for slower titration — only for premature discontinuation.

Extended hold at 0.5 mg or 1.0 mg: Many patients experience clinically meaningful appetite reduction and weight loss at 0.5-1.0 mg without ever reaching 2.4 mg. If a patient is losing 0.5-1% of body weight per week at 1.0 mg with tolerable side effects, there is no imperative to increase further. The minimum effective dose principle applies.

Compounded semaglutide considerations: Compounded semaglutide (available through compounding pharmacies) allows for more granular dose adjustments than the fixed-dose pen system. Starting doses of 0.125 mg (half the standard starting dose) are possible and appropriate for individuals with high GI sensitivity, low body weight, or a history of difficulty tolerating medications.

A slower compounded titration might follow: 0.125 mg (weeks 1-4), 0.25 mg (weeks 5-8), 0.375 mg (weeks 9-12), 0.5 mg (weeks 13-16), then incremental increases by 0.25 mg every 4 weeks as tolerated. This extended schedule takes longer but produces fewer dropouts from intolerable side effects.

Injection day and timing

Consistency matters more than the specific day. Choose a day and stick to it. If a dose is missed, take it within 48 hours of the scheduled day; if more than 48 hours late, skip that dose and resume on the regular schedule.

Time of day: Many practitioners recommend evening injection (e.g., Friday evening) so that the peak nausea window (12-48 hours post-injection) falls during the weekend when reduced activity and food preparation demands make nausea more manageable. Others prefer morning injection on their least-busy day. There is no pharmacological advantage to either timing — it is a practical preference.

Tirzepatide titration protocol

FDA-approved titration schedule (Zepbound)

Week	Dose	Frequency	Purpose
1-4	2.5 mg	Once weekly	Adaptation
5-8	5.0 mg	Once weekly	Low therapeutic range
9-12	7.5 mg	Once weekly	Mid therapeutic range
13-16	10 mg	Once weekly	Upper therapeutic range
17-20	12.5 mg	Once weekly	Advanced dose
21+	15 mg	Once weekly	Maximum dose

Total time to maximum dose: 20-24 weeks (5-6 months).

Tirzepatide-specific notes

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The GIP component adds additional metabolic effects but also introduces a slightly different GI side effect profile. Some patients tolerate tirzepatide better than semaglutide (possibly due to GIP receptor-mediated gastroprotective effects); others experience more pronounced diarrhea (GIP can stimulate intestinal secretion).

The 5.0 mg dose is the first therapeutic dose. The SURMOUNT trials showed that even the lowest therapeutic dose (5 mg) produced clinically significant weight loss. Many patients achieve excellent results at 5-10 mg without reaching 15 mg.

Switching from semaglutide to tirzepatide: If transitioning from semaglutide, the standard approach is to start tirzepatide at 2.5 mg on the week following the last semaglutide dose. Do not attempt to match the "equivalent" dose — the potencies are not directly comparable. Allow the standard titration timeline from the 2.5 mg starting dose.

When to hold a dose

Hold at the current dose (do not escalate) when any of the following are present:

Persistent nausea rated 6 or above on a 10-point scale that has not improved after 3 weeks at the current dose. Mild-to-moderate nausea (1-5/10) that is improving week-over-week is expected and does not require holding.

Vomiting more than once per week at the current dose. Occasional nausea-related vomiting during the first week after an escalation is within normal limits. Persistent vomiting is not.

Significant functional impairment — inability to maintain adequate hydration, inability to eat minimum protein requirements (at least 60 g/day), or missed work/activities due to GI symptoms.

Excessive weight loss velocity — losing more than 1.5% of body weight per week sustained over 2+ weeks. Rapid weight loss increases gallstone risk, promotes lean mass loss, and may indicate the current dose is more aggressive than needed.

Metabolic red flags — new-onset hyperglycemia paradoxically worsening (rare, evaluate for pancreatitis), significant electrolyte abnormalities from vomiting or diarrhea, or heart rate increase greater than 20 bpm from baseline.

When holding, reassess after 2-4 additional weeks. If symptoms have resolved, attempt the next dose escalation. If symptoms persist, consider a half-step increase (e.g., 0.75 mg instead of 1.0 mg for semaglutide, if using compounded formulation) rather than a full step.

GI side effect management during titration

These strategies should be implemented proactively at the start of titration, not reactively after symptoms become severe.

Dietary modifications (start at week 1)

Reduce meal size — aim for 4-5 smaller meals rather than 2-3 large meals. Delayed gastric emptying means a full stomach stays full much longer than usual.

Reduce dietary fat during the first 2-4 weeks of each new dose. Fat independently slows gastric emptying, compounding the GLP-1 effect. Lean proteins, vegetables, and moderate carbohydrates are better tolerated.

Eat slowly and stop at the first sign of fullness. GLP-1 agonists amplify satiety signaling — ignoring early satiety cues and continuing to eat is the fastest route to nausea and vomiting.

Avoid lying down for 30-60 minutes after eating. Horizontal positioning slows gastric emptying further and promotes acid reflux.

Hydration strategy

Minimum 2.5 liters of water daily. Sip consistently rather than drinking large volumes at once (which can trigger nausea with a slow-emptying stomach). Electrolyte supplementation (sodium, potassium, magnesium) is advisable, particularly during periods of reduced food intake or diarrhea.

Supplements

Ginger extract (250 mg with meals or ginger tea between meals) — modest anti-emetic evidence with minimal risk.

Magnesium citrate (200-400 mg daily) — addresses constipation and magnesium depletion from reduced food intake.

Psyllium husk fiber (5-10 g daily) — introduced gradually to support bowel regularity. Start at 5 g and increase over 2 weeks.

Pharmacological support (as prescribed)

Ondansetron (Zofran) 4-8 mg as needed for nausea — effective but should be a temporary bridge during titration, not ongoing therapy.

Famotidine 20-40 mg daily if acid reflux is prominent during titration.

Finding the minimum effective dose

The optimal dose is the lowest dose that achieves:

A sustained weight loss rate of 0.5-1.0% of body weight per week (2-4 lbs/month for most patients). Clinically meaningful improvement in metabolic markers (HbA1c, fasting glucose, triglycerides, blood pressure — depending on the indication). Tolerable side effects that do not impair daily function or nutritional adequacy.

If these criteria are met at an intermediate dose, there is no clinical justification for continuing to escalate. The maximum approved dose exists as a ceiling, not a target. Clinical trials report average results across populations — individual patients may achieve their goals at any point along the titration curve.

Reassess the dose at 3 months and 6 months. If weight loss has plateaued and metabolic goals are not met, a dose increase may be warranted. If goals are met and maintained, continue the current dose. This data-driven approach to dosing produces better long-term outcomes than protocol-driven escalation to the maximum dose regardless of response.